Oishi N, Fleming T R, Laufman L, Ungerleider J S, Natale R B, Einstein A B, Von Hoff D D, Macdonald J S
Cancer Research Center of Hawaii.
Invest New Drugs. 1990 Feb;8(1):93-5. doi: 10.1007/BF00216931.
In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.
在这项多机构的II期研究中，42例晚期结直肠癌患者接受了VM - 26（替尼泊苷）治疗。患者最初每天以60mg/M²的剂量治疗5天，并根据毒性进行剂量调整。观察到1例完全缓解和1例部分缓解，分别持续6个月和4个月。40%的患者出现严重白细胞减少。未观察到与药物相关的死亡病例。在西南肿瘤协作组（SWOG）的这项研究中，VM - 26在晚期结直肠癌中似乎益处极小。
